Gufic BioSciences Ltd
Fri 22/05/2026,15:43:16 | NSE : GUFICBIO
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 287.20
Previous Close
₹ 288.70
Volume
23401
Mkt Cap ( Rs. Cr)
₹2945.30
High
₹ 295.10
Low
₹ 285.05
52 Week High
₹ 407.85
52 Week Low
₹ 268.00
Book Value Per Share
₹ 64.17
Dividend Yield
0.03
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Gufic BioSciences Ltd
Your Vote -
Buy
84.00%
Hold
12.00%
Sell
4.00%
84.00%
25 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Gufic BioSciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Gufic BioSciences - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, Audited Financial Results (Standa
-
Gufic BioSciences - General Updates
-
Gufic BioSciences - Update On Further Investment In Selvax Pty Ltd.
-
Gufic BioSciences has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Gufic BioSciences - Copy of Newspaper Publication
-
Gufic BioSciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Gufic BioSciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Gufic BioSciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,
-
Gufic BioSciences - General Updates
-
Gufic BioSciences - Trading Window
-
Gufic BioSciences - General Updates
-
Gufic receives NMPA China nod for Prilocaine API
-
Gufic BioSciences
-
Gufic Bio gets two patent certificates; stk gains
Key fundamentals
Evaluate the intrinsic value of Gufic BioSciences Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 911.7374 | 849.595 | 659.2153 | 330.3601 | 225.1873 |
| Liabilities | 911.7374 | 849.595 | 659.2153 | 330.3601 | 225.1873 |
| Equity | 10.0278 | 10.0278 | 9.6945 | 9.6945 | 9.6945 |
| Gross Profit | 136.3959 | 145.8714 | 134.6513 | 145.7147 | 83.9195 |
| Net Profit | 69.9328 | 86.1356 | 79.7048 | 95.8401 | 44.2316 |
| Cash From Operating Activities | 122.7777 | -7.4571 | -26.5872 | 104.4442 | 89.0648 |
| NPM(%) | 8.53 | 10.67 | 11.54 | 12.3 | 9.06 |
| Revenue | 819.806 | 806.6657 | 690.6208 | 779.1556 | 487.6987 |
| Expenses | 683.4101 | 660.7943 | 555.9695 | 633.4409 | 403.7792 |
| ROE(%) | 10.86 | 13.38 | 12.38 | 14.89 | 6.87 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 22 Sep 2025 | 0.1 | 10 | 0.03 | 391 |
| 18 Sep 2024 | 0.1 | 10 | 0.03 | 321.05 |
| 24 Aug 2022 | 0.1 | 10 | 0.03 | 243.9 |
| 09 Sep 2021 | 0.1 | 10 | 0.03 | 190.7 |
| 03 Nov 2020 | 0.05 | 5 | 0.03 | 102.1 |
| 20 Sep 2019 | 0.05 | 5 | 0.03 | 59.7 |
| 0.05 | 5 | 0.03 | 145.55 | |
| 28 Aug 2017 | 0.05 | 5 | 0.03 | 66.25 |
| 19 Sep 2016 | 0.05 | 5 | 0.03 | 41.05 |
| 22 Sep 2015 | 0.05 | 5 | 0.03 | 14.05 |
| 18 Sep 2014 | 0.05 | 5 | 0.03 | 20.9 |
| 02 Sep 2013 | 0.05 | 5 | 0.03 | 5.55 |
| 16 Aug 2012 | 0.05 | 5 | 0.03 | 7.75 |
| 16 Sep 2011 | 0.05 | 5 | 0.03 | 6.05 |
| 20 Sep 2010 | 0.05 | 5 | 0.03 | 6.35 |
| 17 Sep 2009 | 0.05 | 5 | 0.03 | 6.35 |
| 11 Dec 2008 | 0.05 | 5 | 0.03 | 4.45 |
| 19 Mar 2008 | 0.05 | 5 | 0.03 | 9.45 |
| 20 Sep 2006 | 0.16 | 16 | 0.03 | 11.7 |
| 22 Sep 2005 | 0.22 | 22 | 0.03 | 29.75 |
Peers
Other companies within the same industry or sector that are comparable to Gufic BioSciences Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.80 | -0.07 | 0.00 | 167.22 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 109.19 | 1.26 | 352.23 | 609.33 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.00 | 0.14 | 0.00 | 3822.54 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 771.80 | 4.77 | 0.00 | 574.61 | -363.15 | 0.00 |
Company Info
Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000 fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.
Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000 fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.
Read More
Parent Organisation
Gufic BioSciences Ltd.
Founded
23/07/1984
Managing Director
Mr.Jayesh P Choksi
NSE Symbol
GUFICBIOEQ
FAQ
The current price of Gufic BioSciences Ltd is ₹ 293.70.
The 52-week high for Gufic BioSciences Ltd is ₹ 295.10 and the 52-week low is ₹ 285.05.
The market capitalization of Gufic BioSciences Ltd is currently ₹ 2945.30. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Gufic BioSciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Gufic BioSciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Gufic BioSciences Ltd shares.
The CEO of Gufic BioSciences Ltd is Mr.Jayesh P Choksi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
